What a Cochrane review says about tirzepatide for weight loss

Why this study matters

Individual trials of tirzepatide (Zepbound, Mounjaro) each cover one group of people. A systematic review gathers every trial that meets set rules and pools the results into one estimate. Cochrane reviews follow strict methods and grade how much trust each result deserves, and this one was funded by a public health body rather than a drug company. It is not a ranking against other medicines.

Who was in the study

The review included 9 randomized controlled trials with 7111 adults living with obesity. Participants were aged 36.1 to 65.25 years on average across the trials and came mainly from middle- and high-income countries. Seven trials focused on specific groups such as type 2 diabetes, prediabetes, chronic heart failure, obstructive sleep apnea and different racial populations. Each trial had to follow people for at least six months. The search ended on 17 December 2024 (R32-C57).

What the researchers did

The authors searched five research databases and two trial registries. They kept only randomized controlled trials, which are studies where people are assigned by chance to a treatment or a comparison group. Eight trials compared tirzepatide with placebo, a dummy injection with no medicine in it. One compared it with semaglutide. Tirzepatide was given by weekly injection at doses from 5 mg to 15 mg.

Results were pooled using a random-effects meta-analysis, a statistical way of combining results from several trials. The certainty of each result was rated high, moderate, low or very low using a system called GRADE.

What they found

The main comparison was tirzepatide versus placebo. Results were split into medium term (12 to 18 months, 8 trials) and long term (3.5 years, 1 trial with 1032 people).

Over the medium term, tirzepatide likely reduced body weight by a mean difference of 16.03 percentage points compared with placebo (95% CI -18.91 to -13.14; 8 trials, 6317 people; moderate certainty) (R32-C57). A confidence interval, or CI, is the range within which the true result most likely sits. People on tirzepatide were 3.60 times as likely to lose at least 5% of their weight (95% CI 2.44 to 5.30).

A risk ratio compares how often something happened on tirzepatide with how often it happened on placebo. A value of 1 means no difference. The review judged that tirzepatide likely made little to no difference to MACE or death over the medium term. Physical function on a quality-of-life questionnaire improved by 9.91 points (95% CI 7.81 to 12.02), which the review described as likely little to no clinically important difference.

Over the long term, from the single 3.5-year trial, tirzepatide likely reduced body weight by 15.66 percentage points more than placebo (95% CI -19.14 to -12.18; moderate certainty). Long-term estimates for serious adverse events (risk ratio 1.14, 95% CI 0.79 to 1.65) and death (risk ratio 0.83, 95% CI 0.22 to 3.17) were rated very low and low certainty.

Side effects and people who stopped

Over the medium term, tirzepatide may have increased non-serious adverse events (risk ratio 1.33; low certainty) and stopping because of side effects (risk ratio 2.06; low certainty). For serious adverse events, the estimated risk ratio was 0.99 (95% CI 0.88 to 1.12), but the review rated this evidence very low certainty, so the number does not establish that serious harms were absent (R32-C58). The summary does not report overall discontinuation.

What this study does not tell you

• It pools trials with different populations, including people with diabetes, heart failure and sleep apnea, so the single number hides real differences between trials.
• All nine trials reported major manufacturer involvement in design, conduct, analysis or writing. The authors say this raises concerns about conflicts of interest.
• The search ended on 17 December 2024, so later trials are not included.
• The long-term result rests on one trial.
• The review does not rank tirzepatide against other medicines. Its only active comparison was one trial against semaglutide.
• We reviewed the abstract only, so the details behind each pooled number were not checked.

What it means in Canada

This review gives Canadian readers a single, independently funded picture of what the tirzepatide trials show together. It does not change what any one trial found, and it does not describe how the medicine is used or paid for here. See tirzepatide in Canada, public drug coverage by province and compare services.

Related reading

Other studies in this library that bear on the same question.

Source